Effect of rosuvastatin on cholestasis-induced hepatic injury in rat livers

Journal of Biochemical and Molecular Toxicology

Volumn 24, Issue 2, 2010, Pages 89-94

  Awad, Azza S ^a   Kamel, Rehab ^b  

^a Al Azhar University   (Egypt)

^b Ein Helwan   (Egypt)

Author keywords

Bile duct ligation; Biliary obstruction; Cholestasis; Inflammation; Lipid peroxidation; Oxidative stress; Rosuvastatin

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CATALASE; GAMMA GLUTAMYLTRANSFERASE; GLUTATHIONE TRANSFERASE; LIPID PEROXIDE; NITRIC OXIDE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); ROSUVASTATIN; SUPEROXIDE DISMUTASE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILE DUCT; BILE DUCT LIGATION; BILIRUBIN BLOOD LEVEL; CELL INFILTRATION; CHOLESTASIS; COMPARATIVE STUDY; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HISTOPATHOLOGY; INFLAMMATION; INFLAMMATORY CELL; INFLAMMATORY INFILTRATE; LIPID PEROXIDATION; LIVER; LIVER INJURY; MALE; NONHUMAN; RAT; SHAM PROCEDURE;

ANIMALIA; RATTUS;

EID: 77950851232     PISSN: 10956670     EISSN: 10990461     Source Type: Journal    
DOI: 10.1002/jbt.20315     Document Type: Article

References (46)

1. Paumgartner G. Medical treatment of cholestatic liver diseases: From pathobiology to pharmacological targets. World J Gastroenterol 2006;12(28):4445-4451. (Pubitemid 44256328)
2. Zollner G, Trauner M. Mechanisms of cholestasis. Clin Liver Dis 2008;12(1):1-26. (Pubitemid 351163143)
3. Assimakopoulos SF, Vagianos CE. Bile duct ligation in rats: A reliable model of hepatorenal syndrome?World J Gastroenterol 2009;15(1):121-123.
4. Aviram M, Rosenblat M, Bisgaier CL, Newton RS. Atorvastatin and gemfibrozil metabolites, but not the parent drugs are potent antioxidants against lipoprotein oxidation. Atherosclerosis 1998;138:272-280. (Pubitemid 28314098)
5. Ridker PM, Cannon CP, Morrow D, Rifai N, Rose LM, McCabe CH, Pfeffer MA, Braunwald E. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 2005;352:20-28. (Pubitemid 40075677)
6. Laufs U, La Fata V, Plutzky J, Liao JK. Upregulation of endothelial nitric oxide synthase byHMGCoA reductase inhibitors. Circulation 1998;97:1129-1135. (Pubitemid 28152885)
7. Edwards CJ, Hart DJ, Spector TD. Oral statins and increased bone-mineral density in postmenopausal women. Lancet 2000;355(9222):2218-2219.
8. Rosenson RS. Non-lipid lowering effects of statins on atherosclerosis. Curr Cardiol Rep 1999;1(3):228-232.
9. Vaughan CJ, Delanty N. Neuroprotective properties of statins in ischemia and stroke. Stroke 1999;30:1969-1973. (Pubitemid 29411843)
10. Balmer ML, Dufour JF. Treatment of hypercholesterolemia in patients with primary biliary cirrhosismight be more beneficial than indicated. Swiss Med Wkly 2008;138(29-30):415-419.
11. IkedaY, YoungLH, LeferAM. Rosuvastatin, a newHMGCoA reductase inhibitor, protects ischemic reperfused myocardium in normocholesterolemic rats. J Cardiovasc Pharmacol 2003;41:649-656. (Pubitemid 36373804)
12. Bulhak A, Sjoquist PO, Pernow J. Rosuvastatin protects the myocardium against ischaemia-reperfusion injury via inhibition of GGPP synthesis. Cardiovasc J S Afr 2004;15:S11.
13. Weinberg EO, Scherrer-Crosbie M, Picard MH, Nasseri BA, MacGillivray C, Gannon J, Lian Q, Bloch KD, Lee RT. Rosuvastatin reduces experimental left ventricular infarct size after ischemia-reperfusion injury but not total coronary occlusion. Am J Physiol Heart Circ Physiol 2005;288:H1802-H1809. (Pubitemid 40418007)
14. Bulhak AA, GourineAV, GononAT, Sjoquist PO,ValenG, Pernow J. Oral pre-treatment with rosuvastatin protects porcine myocardium from ischaemia/reperfusion injury via a mechanism related to nitric oxide but not to serum cholesterol level. Acta Physiol Scand 2005;183:151-159. (Pubitemid 40203608)
15. NezasaK, Higaki K, Matsumura T, InazawaK,Hasegawa H, Nakano M, Koike M. Liver-specific distribution of rosuvastatin in rats: Comparison with pravastatin and simvastatin. Drug Metab Dispos 2002;30(11):1158-1163. (Pubitemid 35265820)
16. Martin PD, Warwick MJ, Dane AL, Hill SJ, Giles PB, Phillips PJ, Lenz E. Metabolism, excretion, and pharmacokinetics of rosuvastatin in healthy volunteers. Clin Ther 2003;25(11): 2822-2835. (Pubitemid 37510592)
17. Schuster H. Rosuvastatin: A highly effective new 3- hydroxy-3- methylglutaryl coenzyme A reductase inhibitor. Review of clinical trial data at 10-40 mg doses in dyslipidemic patients. Cardiology 2003;99:126-139.
18. McCormick AD, McKillop D, Butters CJ, et al. ZD452: An HMG-CoA reductase inhibitor free of metabolically mediated drug interactions. Metabolic studies in human in vitro systems. J Clin Pharmacol 2000;40(9):1055.
19. Uchiyama M, Mihara M. Determination of malonldehyde precursor in tissues by thiobarbituric acid test.Anal Biochem 1978;86:271-278. (Pubitemid 9050395)
20. Habig WH, Pabst MJ, Jakoby WB. Glutathione-Stransferase. The first enzymatic step in mercapturic acid formation. J Biol Chem 1974;249:7130-7139.
21. Marklund SL. Pyrogallol autooxidation. In: Greenwald RA, editor. Handbook of methods for oxygen radical research. Boca Raton, FL: CRC Press; 1985. pp 243-247.
22. Benson AM, Hunkeler MJ, Talalay P. Increase of NAD(P)H: Quinone reductase by dietary antioxidants: Possible role in protection against carcinogenesis and toxicity. Proc Natl Acad Sci USA 1980;77(9):5216-5220. (Pubitemid 11195538)
23. Clairborne A. Catalase activity. In:Greenwald RA, editor. Handbook of methods for oxygen radical research. Boca Raton, FL: CRC Press; 1985. pp 283-284.
24. Raghavendra V, Agrewala JN, Kulkarni SK. Melatonin reversal of lipopolysacharides-induced thermal and behavioral hyperalgesia in mice. Eur J Pharmacol 2000;395(1):15-21. (Pubitemid 30227336)
25. Lowry OH, Rosebrough NJ, Forr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem 1951;193:265-275.
26. Banchroft JD, Stevens A, Turner DR. Theory and practice of histological techniques, 4th ed. Churchil Livingstone: New York; 1996.
27. Krahenbuhl S, Talos C, Lauterburg BH, Reichen J. Reduced antioxidative capacity in liver mitochondria from bile duct ligated rats. Hepatology 1995;22:607-612.
28. Sokol RJ, Devereaux M, Khandwala R, O'Brien K. Evidence for involvement of oxygen free radicals in bile acid toxicity to isolated rat hepatocytes. Hepatology 1993;17:869-881. (Pubitemid 23150097)
29. Dahm LJ, Hewett JA, Roth RA. Bile and bile salts potentiate superoxide anion release fromactivated rat peritoneal neutrophils. Toxicol Appl Pharmacol 1988;95:82-92.
30. Gallo-Torres HE. Obligatory role of bile for the intestinal absorption of vitamin E. Lipids 1970;5:379-384.
31. Singh S, Shackleton G, Ah-Sing E, Chakraborty J, Bailey ME. Antioxidant defenses in the bile duct-ligated rat. Gastroenterology 1992;103:1625-1629.
32. Ajith TA, Riji T, Anu V. In vitro anti-oxidant and DNA protective effects of the novel 3-hydroxy-3- methylglutaryl coenzyme A reductase inhibitor rosuvastatin. Clin Exp Pharmacol Physiol 2008;35(5-6):625-629. (Pubitemid 351490097)
33. Schupp N, Schmid U, Heidland A, Stopper H. Rosuvastatin protects against oxidative stress and DNA damage in vitro via upregulation of glutathione synthesis. Atherosclerosis 2008;199(2):278-287.
34. Gaillard T, Mulsch A, Busse R, KleinH,DeckerK.Regulation of nitric oxide production by stimulated rat Kupffer cells. Pathobiology 1991;59:280-283.
35. Ishizaki-Koizumi S, Sonaka I, Takei Y, Ikejima K, Sato N. The glycine analogue, aminomethanesulfonic acid, inhibits LPS-induced production of TNF-a in isolated rat Kupffer cells and exerts hepatoprotective effects in mice. Biochem Biophys Res Commun 2004;322:514-519. (Pubitemid 39490334)
36. Jaeschke H, Gores GJ, Cederbaum AI, Hinson JA, Pessayre D, Lemasters JJ. Mechanisms of hepatotoxicity. Toxicol Sci 2002;65:166-176. (Pubitemid 34121108)
37. Li J, Billiar TR. Nitric oxide. IV: Determinants of nitric oxide protection and toxicity in liver. Am J Physiol 1999;276(5 Pt 1):G1069-G1073. (Pubitemid 29251903)
38. Di Napoli P, Taccardi AA, Grilli A, De Lutiis MA, Barsotti A, Felaco M, De Caterina R. Chronic treatment with rosuvastatin modulates nitric oxide synthase expression and reduces ischemia-reperfusion injury in rat hearts. Cardiovasc Res 2005;66:462-471. (Pubitemid 40725758)
39. Demirbilek S, Tas E, Gurunluoglu K, Akin M, Aksoy RT, Emre MH, Aydin NE, Ay S, Ozatay N. Fluvastatin reduced liver injury in rat model of extrahepatic cholestasis. Pediatr Surg Int 2007;23(2):155-162. (Pubitemid 46175220)
40. Dold S, Laschke MW, Lavasani S, Menger MD, Jeppsson B, Thorlacius H. Simvastatin protects against cholestasisinduced liver injury. Br J Pharmacol 2009 Jan 13. [Epub ahead of print] 2009Feb;156(3):466-474.
41. Siegel D, Ross D. Immunodetection of NAD(P)H:quinone oxidoreductase 1 (NQO1) in human tissues. Free Radic Biol Med 2000;29:246-253.
42. Strassburg A, Strassburg CP, Manns MP, Tukey RH. Differential gene expression of NAD(P)H:quinone oxidoreductase and NRH:quinine oxidoreductase in human hepatocellular and biliary tissue. Mol Pharmacol 2002;61:320-325. (Pubitemid 34112806)
43. Ross D, Kepa JK, Winski SL, Beall HD, Anwar A, Siegel D. NAD(P)H:quinone oxidoreductase 1 (NQO1): Chemoprotection, bioactivation, gene regulation and genetic polymorphisms. Chem Biol Interact 2000;129: 77-97. (Pubitemid 32061055)
44. Aleksunes LM, Slitt AM, Cherrington NJ, Thibodeau MS, Klaassen CD, Manautou JE. Differential expression of mouse hepatic transporter genes in response to acetaminophen and carbon tetrachloride. Toxicol Sci 2005;83:44-52.
45. Heijne WH, SlittAL, van Bladeren PJ, Groten JP, Klaassen CD, Stierum RH, van Ommen B. Bromobenzene induced hepatotoxicity at the transcriptome level. Toxicol Sci 2004;79:411-422.
46. Aleksunes LM, Goedken MJ, Manautou JE. Upregulation of NAD(P)H quinone oxidoreductase 1 during human liver injury. World J Gastroenterol 2006;12:1937- 1940.